1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Nipro Medical Device Company Intelligence Report

Nipro Medical Device Company Intelligence Report

  • April 2013
  • -
  • Espicom Business Intelligence
  • -
  • 26 pages

Nipro Corporation, based in Osaka, Japan, was established in July 1954 and is principally engaged in the manufacture and marketing of medical devices, pharmaceuticals and glass products. The company also operated supermarkets and consumer drug stores in Japan, but sold these operations in June 2006.

Nipro’s core medical device activities, including dialysis devices, intervention anaesthesiology devices, infusion and diagnostics products, and cardiopulmonary products, are undertaken by its Medical division, which is the group’s largest business segment, accounting for 68.4% of the group’s consolidated net sales in fiscal 2011 (FY2011, ended 31st March 2012). The company is also moving further into the fields of diabetes-related products and artificial heart and lung devices. The acquisition of Home Diagnostics (renamed Nipro Diagnostics) in March 2010 enabled Nipro to make a full-scale entry into the blood glucose meter and ancillaries market.

Through its Pharmaceutical division, Nipro is involved in the generic pharmaceutical industry with the sale of injection, oral and percutaneous absorption drugs. The division also produces dialysis-related medical products, such as dialysis solutions. The Materials segment sells internal glass sections for vacuum flasks, glass tubes for ampoule and vial production, vials and other glass products. Nipro also operates an ‘Other’ business segment that includes sales of machinery for manufacture of medical equipment and income from the rental of real estate. The Pharmaceutical, Materials and Other divisions, which represented approximately 19%, 13% and under 1% of total sales, respectively, in FY2011, are not covered in detail in this report.


The Nipro Medical Device Company Report provides a full review of the company's medical device activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures and litigation. Sections are also included on products, corporate strategy and R&D.


Whatever your interest or involvement, evaluating the performance, success, failures and developments of medical companies is critical. Espicom’s Medical Device Company Reports have been regularly published for over 20 years, and these critically acclaimed and respected management reports provide a complete review of leading players in the field.


Key Benefits

Evaluate competitive threats
Maximise product and market opportunities
Identify collaborators and strategic partners
Understand the operating market environment
Benchmark your performance against competitors
Coverage Overview

Key contact information
Introduction to Nipro and its current activities
Summary of its financial performance
Key recent events in an “at a glance” format
Strategic Focus

The company’s aims and its areas of focus
Financial Review

Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location
Product Overview

Core product areas, key brands, product approvals and launches
Identifies the company’s major competitors
Research and Development

How much has been invested in R&D?
Where is the research based?
What alliances and agreements does Nipro have and with whom?
Manufacturing and Distribution

Identifying the company’s manufacturing locations
Sales and marketing facilities
Agreements

With whom has Nipro reached agreements and what do they involve?
Key contracts awarded
Mergers and Acquisitions


Minority Divestments

Litigation

Key Corporate Events


The report was produced as part of Medical Device Companies Analysis (MDCA).

Table Of Contents

Nipro Medical Device Company Intelligence Report
Table of Contents OVERVIEW 2 STRATEGIC FOCUS 3 Medium- To Long-Term Strategy 3 Strategy to Fiscal 2014 3 Espicom View 4 FINANCIAL REVIEW 5 Fiscal 2011 Financial Results 5 Five-Year Financial Data 8 Outlook 9 Employees 9 PRODUCTS 10 Dialysis, Interventional Anaesthesiology, Infusion, Diagnostic and Cardiopulmonary Products 11 Diabetes Management 15 RESEARCH AND DEVELOPMENT 16 RandD Expenditure 16 Development Activities 16 Artificial Organ-Related Development 16 Diagnostic Product-Related Development 16 MANUFACTURING AND DISTRIBUTION 17 Manufacturing 17 Japan 17 Brazil 17 China 17 India 18 Indonesia 18 Bangladesh 18 Thailand 18 US 18 Sales and Distribution 19 AGREEMENTS 20 NextGen Healthcare Information Systems 20 Hugo Technology 20 InfraReDx 20 NeuroMetrix 21 Cellnovo 21 Arkray 21 Thoratec 21 MERGERS AND ACQUISITIONS 23 Diabetes Australia-NSW 23 Home Diagnostics and Nipro Diabetes Systems 23 Home Diagnostics 23 Toyobo's VAD Manufacturing Business 23 DIVESTITURES 24 Bipha Corporation 24 KEY CORPORATE EVENTS 25 List of Tables Recent Key Events 2 Nipro Group - Annual Financial Results, Fiscal Years 2007-2011 5 Nipro - Net Sales and Operating Income by Business Segment, Fiscal Years 2007-2011 6 Nipro - Annual Group Sales by Geographic Area, Fiscal Years 2007-2011 7 Nipro - Five-Year Financial Summary 8 Nipro - Forecast Financial Results, FY2012 9 Nipro - Annual Employee Figures 9 Nipro - Sales Breakdown by Business Segment, FY2011 10 Nipro - Annual RandD Expenditure, Fiscal Years 2007-2011 16 Nipro - Principal Medical Equipment Manufacturing Facilities, March 2012 19 Agreements Summary 20 Mergers and Acquisitions Summary 23 List of Charts Nipro Group - Annual Sales and Operating Income, Fiscal Years 2007-2011 5 Nipro Medical Equipment Division - Net Sales and Operating Income, Fiscal Years 2007-2011 6 Nipro Group - Annual Sales by Geographic Area, Fiscal Years 2007-2011 7

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.